Nasdaq
$26.86▲ 0.04%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.70BShares out 63.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 10.13Pre-market26.10.13 19:018-KKey event#●●●#●●●
Zenas BioPharma, Inc.Bullish
Zenas BioPharma announced new data from the Phase 3 INDIGO open-label extension study of obexelimab for IgG4-related disease. The results demonstrated sustained clinical activity, including reduced glucocorticoid toxicity and the maintenance of vaccine responses during treatment-free windows.…more
$26.86+0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.11After-hours26.09.12 05:49S-3ASROffering
Zenas BioPharma, Inc.
Zenas BioPharma has filed a Form S-3ASR registration statement for the resale of up to 7,000,000 shares of common stock held by its existing stockholder, InnoCare Pharma. This filing is intended to fulfill contractual obligations under a subscription agreement dated October 7, 2025, and the company will not receive any proceeds from these sales.…more
$26.86+0.04%vs prev closeView filingShare - 9.11After-hours26.09.12 05:47S-8Offering
Zenas BioPharma, Inc.
Zenas BioPharma has registered an additional 600,000 shares of common stock to support its 2026 Inducement Plan for new employee equity awards. This increase was approved by the Board of Directors on August 5, 2026, and is intended to facilitate compensation for new hires.…more
$26.86+0.04%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.16After-hours26.10.17 05:15#●●●
Zenas BioPharma Announces Inducement Grants for New Hires
Zenas BioPharma has granted 74,900 restricted stock units (RSUs) to newly hired employees as an inducement for their employment. This grant follows standard Nasdaq listing rules for talent acquisition.…more
$26.86+0.04%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.12Pre-market26.10.12 20:00
●●●●●●●● ●●●●● ●●●●●●
Zenas BioPharma announced new Phase 3 open-label extension data demonstrating sustained clinical activity and reduced glucocorticoid toxicity for its investigational drug, obexelimab. While these findings support the drug's potential for long-term IgG4-RD management, it remains in the clinical development stage.…more
$26.86+0.04%vs prev close - 10.7Pre-market26.10.07 20:05
●●●●●●●● ●●●●● ●●●●●●
Zenas BioPharma will present clinical data and trial designs for its MS candidates, orelabrutinib and obexelimab, at the upcoming MSToronto2026 conference. This event focuses on academic dissemination of clinical progress rather than immediate regulatory approval or financial impact.…more
$26.86+0.04%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report